Daniel Glynn

Daniel Glynn

Company: concept life sciences

Job title: research leader


The development of BRPF1 degraders as a potential treatment for AML 12:00 pm

The key areas for the development and designing of PROTAC degraders The rationale for degradation of BRPF1 in AML and beyond The biological characterisation of newly synthesised compoundsRead more

day: Day 2 AM - Stream A

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.